Vaginal ring tested for safety in overweight PCOS women

NCT ID NCT04257500

Completed Disease control Sponsor: Andrea Roe, MD, MPH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using a contraceptive vaginal ring (NuvaRing) for 16 weeks affects the risk of metabolic syndrome in overweight or obese women with polycystic ovary syndrome (PCOS). Researchers enrolled 22 participants and measured changes in blood pressure, waist size, blood sugar, and cholesterol. The goal was to see if this birth control method is safe for this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: etonogestrel/ethinyl estradiol vaginal ring (NuvaRing)
What this could lead to: If successful, this could show that the vaginal ring is a safe contraceptive option for overweight/obese women with PCOS without raising metabolic syndrome risk.
What could go wrong: This was a small, completed Phase 4 study with only 22 participants, so results may not apply to all women. The ring may still affect cholesterol or blood pressure in some individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYSTIC OVARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYCYSTIC OVARY SYNDROME

Contacts and locations

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.